Pharvaris (NASDAQ:PHVS) Releases Earnings Results, Beats Estimates By $0.12 EPS

Pharvaris (NASDAQ:PHVS) issued its quarterly earnings results on Tuesday. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12, Zacks reports.

Pharvaris Price Performance

Shares of NASDAQ:PHVS traded up $1.30 during trading on Tuesday, reaching $31.25. 321,673 shares of the stock were exchanged, compared to its average volume of 218,697. Pharvaris has a 1-year low of $14.59 and a 1-year high of $31.65. The stock has a fifty day moving average of $27.84 and a two-hundred day moving average of $26.36. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -9.27 and a beta of -2.34.

Insider Buying and Selling at Pharvaris

In other Pharvaris news, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40. Following the transaction, the director directly owned 355,167 shares in the company, valued at approximately $10,768,663.44. This trade represents a 7.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Peng Lu sold 15,000 shares of the firm’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the transaction, the insider directly owned 66,083 shares in the company, valued at $1,998,349.92. The trade was a 18.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 150,659 shares of company stock worth $4,489,587. 11.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pharvaris

Institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC bought a new stake in Pharvaris in the 4th quarter valued at about $77,000. JPMorgan Chase & Co. boosted its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. Public Employees Retirement System of Ohio increased its stake in shares of Pharvaris by 39.3% in the third quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock worth $156,000 after purchasing an additional 1,769 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its stake in shares of Pharvaris by 50.1% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 8,239 shares of the company’s stock worth $229,000 after purchasing an additional 2,750 shares in the last quarter. Finally, Alliancebernstein L.P. bought a new stake in shares of Pharvaris in the third quarter valued at approximately $224,000.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Wall Street Zen downgraded Pharvaris from a “sell” rating to a “strong sell” rating in a report on Monday, April 13th. Wolfe Research assumed coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price on the stock. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Wedbush lifted their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.73.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.